PPARA and metabolic dysfunction-associated steatotic liver disease: Of special note, recent evidence suggests a possible involvement of epigenetic silencing mechanisms in PPARα functions in MASLD progression which may counteract therapeutic actions of PPAR ligands (Theys et al., 2022).